NewsBenzingaMicrochip Technology und Navitas Semiconductor kooperieren bei einem 800-V-DC-zu-6-V-DC-Referenzdesign für KI-Rechenzentrums-Rack-Stromversorgungsanwendungen, um die digitalen Leistungsregelungs- und Sicherheitstechnologien von MCHP mit den... Microchip Technology und Navitas Semiconductor kooperieren bei einem 800-V-DC-zu-6-V-DC-Referenzdesign für KI-Rechenzentrums-Rack-Stromversorgungsanwendungen, um die digitalen Leistungsregelungs- und Sicherheitstechnologien von MCHP mit den... Benzinga 2026.10.05 10:58 (GMT+0) Open on Benzinga Other news ENSv2 Activation Proposal Would Halt New ENSv1 Registrations Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s Reported Sunday, Stellantis Previews Six Of Nine Concept Cars Debuting At Paris Motor Show October 12-18, Highlighting FaSTLAne 2030 Strategy Results Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations Hong Kong to list second spot Solana ETF on October 13
Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Care
Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s
Reported Sunday, Stellantis Previews Six Of Nine Concept Cars Debuting At Paris Motor Show October 12-18, Highlighting FaSTLAne 2030 Strategy Results
Reported Sunday, BridgeBio Presents Acoramidis Data At HFSA 2026 Showing 18% Lower Composite Risk Versus Tafamidis In Real-World Study Of 2,684 ATTR-CM Patients And Mortality Rising After Cardiovascular Hospitalizations
